MX2014011836A - Administracion subcutanea de iduronato-2-sulfatasa. - Google Patents

Administracion subcutanea de iduronato-2-sulfatasa.

Info

Publication number
MX2014011836A
MX2014011836A MX2014011836A MX2014011836A MX2014011836A MX 2014011836 A MX2014011836 A MX 2014011836A MX 2014011836 A MX2014011836 A MX 2014011836A MX 2014011836 A MX2014011836 A MX 2014011836A MX 2014011836 A MX2014011836 A MX 2014011836A
Authority
MX
Mexico
Prior art keywords
iduronate
sulfatase
subcutaneous administration
present
provides
Prior art date
Application number
MX2014011836A
Other languages
English (en)
Inventor
Thomas Mccauley
Hongsheng Xie
Brian Felice
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of MX2014011836A publication Critical patent/MX2014011836A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención provee, entre otras cosas, composiciones, kits y métodos para suministro subcutáneo de enzimas lisosomales para el tratamiento efectivo de enfermedades de almacenamiento lisosomal; en algunas modalidades, la presente invención provee métodos para tratar el síndrome de Hunter mediante la administración subcutánea de una proteína de reemplazo iduronato-2-sulfatasa (l2S); en algunas modalidades, la presente invención provee un kit que comprende una disposición de componentes para administrar subcutáneamente la proteína iduronato-2-sulfatasa (l2S).
MX2014011836A 2012-03-30 2013-03-14 Administracion subcutanea de iduronato-2-sulfatasa. MX2014011836A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261618638P 2012-03-30 2012-03-30
PCT/US2013/031662 WO2013148277A1 (en) 2012-03-30 2013-03-14 Subcutaneous administration of iduronate- 2-sulfatase

Publications (1)

Publication Number Publication Date
MX2014011836A true MX2014011836A (es) 2015-03-09

Family

ID=49261057

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011836A MX2014011836A (es) 2012-03-30 2013-03-14 Administracion subcutanea de iduronato-2-sulfatasa.

Country Status (8)

Country Link
US (1) US9603908B2 (es)
EP (1) EP2830642B1 (es)
AU (1) AU2013240306A1 (es)
BR (1) BR112014024358A8 (es)
CA (1) CA2868466A1 (es)
EA (1) EA201491578A1 (es)
MX (1) MX2014011836A (es)
WO (1) WO2013148277A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX366336B (es) 2012-11-02 2019-07-05 Celgene Corp Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
MY189601A (en) * 2015-05-13 2022-02-18 Celgene Corp Treatment of beta-thalassemia using actrii ligand traps
KR20170004814A (ko) 2015-07-02 2017-01-11 주식회사 녹십자 헌터증후군 치료제
WO2017003270A1 (ko) * 2015-07-02 2017-01-05 주식회사 녹십자 헌터증후군 치료제 및 치료방법
DK3397270T3 (da) * 2015-12-30 2024-05-06 Green Cross Corp Sammensætninger til anvendelse i behandlingen af hunters syndrom
CA3076369A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
US11268079B2 (en) * 2018-08-01 2022-03-08 Integrated Micro-Chromatography Systems, Inc. Compositions of beta-glucuronidase enzyme blends with enhanced enzymatic activity and methods of preparation thereof
US11421210B2 (en) 2018-10-08 2022-08-23 Integrated Micro-Chromatography Systems, Inc. Chimeric and other variant beta-glucuronidase enzymes with enhanced properties

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
NZ603330A (en) 2003-02-11 2015-02-27 Shire Human Genetic Therapies Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
US20050208090A1 (en) 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
JP2013506697A (ja) 2009-10-06 2013-02-28 アンジオケム インコーポレーテッド 治療薬を輸送するための組成物と方法
HUE044865T2 (hu) 2009-10-09 2019-11-28 Armagen Inc Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére
KR20230159646A (ko) 2010-06-25 2023-11-21 샤이어 휴먼 지네틱 테라피즈 인크. 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들

Also Published As

Publication number Publication date
EP2830642B1 (en) 2019-08-28
AU2013240306A1 (en) 2014-10-09
BR112014024358A2 (pt) 2017-12-05
CA2868466A1 (en) 2013-10-03
EA201491578A1 (ru) 2015-04-30
US20150086526A1 (en) 2015-03-26
WO2013148277A1 (en) 2013-10-03
EP2830642A4 (en) 2015-12-02
BR112014024358A8 (pt) 2018-01-23
EP2830642A1 (en) 2015-02-04
US9603908B2 (en) 2017-03-28

Similar Documents

Publication Publication Date Title
MX2014011836A (es) Administracion subcutanea de iduronato-2-sulfatasa.
UA115649C2 (uk) Способи та композиції для доставки до цнс ідуронат-2-сульфатази
WO2013084000A3 (en) Exosomes for delivery of biotherapeutics
AU2011270668A8 (en) CNS delivery of therapeutic agents
GB2511713A (en) Methods of treating behavioral symptoms of neurological and mental disorders
MX2013000321A (es) Suministro al sistema nervioso central de agentes terapeuticos.
EA201492055A1 (ru) ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
WO2019006005A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
IN2014MN00333A (es)
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
AU2018205186B2 (en) Angiotensin in treating brain conditions
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
MX344795B (es) Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a.
MX352824B (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
MX2021013582A (es) Composiciones que comprenden agentes biologicamente activos y sales biliares.
EA201391063A1 (ru) Аполипопротеин a-iv в качестве антидиабетического пептида
MX2019009846A (es) Iduronato-2-sulfatasa para usarse en el tratamiento del deterioro cognitivo del sindrome de hunter mediante suministro intratecal.
MX2016005720A (es) Composiciones y metodos para administracion de una enzima a las vias respiratorias de un sujeto.
PH12018550102A1 (en) Methods and compositions for treating hunter syndrome
MX2019013207A (es) Metodos y composiciones para tratar la endometriosis y sintomas asociados a la endometriosis.
MX364643B (es) USO DEL COMPUESTO FTY720: 2-amino - 2-[2-(4-octilfenil) etil] propano-1,3-diol (fingolimod) EN EL TRATAMIENTO DE PACIENTES CON DIABETES DE TIPO 2.
EA201892473A1 (ru) In vivo использование хондроитиназы и/или гиалуронидазы для улучшения доставки агента
EA201491047A1 (ru) Лечение когнитивных нарушений при синдроме хантера путем интратекальной доставки идуронат-2-сульфатазы
EA202192397A2 (ru) Интраназальные биоадгезивные тестостероновые составы в виде гелей и их применение для лечения мужского гипогонадизма
BR112012033205B8 (pt) Uso de uma composição compreendendo agentes terapêuticos para liberação ao sistema nervoso central